Cargando…

MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway

AIMS/HYPOTHESIS: Type 2 diabetes is associated with a reduction in skeletal muscle mass; however, how the progression of sarcopenia is induced and regulated remains largely unknown. We aimed to find out whether a specific microRNA (miR) may contribute to skeletal muscle atrophy in type 2 diabetes. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shu, Yang, Guangyan, Wu, Han, Kang, Lin, Xiang, Jiaqing, Zheng, Peilin, Qiu, Shanhu, Liang, Zhen, Lu, Yan, Jia, Lijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803817/
https://www.ncbi.nlm.nih.gov/pubmed/34913989
http://dx.doi.org/10.1007/s00125-021-05616-y
_version_ 1784642951459110912
author Yang, Shu
Yang, Guangyan
Wu, Han
Kang, Lin
Xiang, Jiaqing
Zheng, Peilin
Qiu, Shanhu
Liang, Zhen
Lu, Yan
Jia, Lijing
author_facet Yang, Shu
Yang, Guangyan
Wu, Han
Kang, Lin
Xiang, Jiaqing
Zheng, Peilin
Qiu, Shanhu
Liang, Zhen
Lu, Yan
Jia, Lijing
author_sort Yang, Shu
collection PubMed
description AIMS/HYPOTHESIS: Type 2 diabetes is associated with a reduction in skeletal muscle mass; however, how the progression of sarcopenia is induced and regulated remains largely unknown. We aimed to find out whether a specific microRNA (miR) may contribute to skeletal muscle atrophy in type 2 diabetes. METHODS: Adeno-associated virus (AAV)-mediated skeletal muscle miR-193b overexpression in C57BLKS/J mice, and skeletal muscle miR-193b deficiency in db/db mice were used to explore the function of miR-193b in muscle loss. In C57BL/6 J mice, tibialis anterior-specific deletion of 3-phosphoinositide-dependent protein kinase-1 (PDK1), mediated by in situ AAV injection, was used to confirm whether miR-193b regulates muscle growth through PDK1. Serum miR-193b levels were also analysed in healthy individuals (n = 20) and those with type 2 diabetes (n = 20), and correlations of miR-193b levels with HbA(1c), fasting blood glucose (FBG), body composition, triacylglycerols and C-peptide were assessed. RESULTS: In this study, we found that serum miR-193b levels increased in individuals with type 2 diabetes and negatively correlated with muscle mass in these participants. Functional studies further showed that AAV-mediated overexpression of miR-193b induced muscle loss and dysfunction in healthy mice. In contrast, suppression of miR-193b attenuated muscle loss and dysfunction in db/db mice. Mechanistic analysis revealed that miR-193b could target Pdk1 expression to inactivate the Akt/mammalian target of rapamycin (mTOR)/p70S6 kinase (S6K) pathway, thereby inhibiting protein synthesis. Therefore, knockdown of PDK1 in healthy mice blocked miR-193b-induced inactivation of the Akt/mTOR/S6K pathway and impairment of muscle growth. CONCLUSIONS/INTERPRETATION: Our results identified a previously unrecognised role of miR-193b in muscle function and mass that could be a potential therapeutic target for treating sarcopenia. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05616-y.
format Online
Article
Text
id pubmed-8803817
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88038172022-02-02 MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway Yang, Shu Yang, Guangyan Wu, Han Kang, Lin Xiang, Jiaqing Zheng, Peilin Qiu, Shanhu Liang, Zhen Lu, Yan Jia, Lijing Diabetologia Article AIMS/HYPOTHESIS: Type 2 diabetes is associated with a reduction in skeletal muscle mass; however, how the progression of sarcopenia is induced and regulated remains largely unknown. We aimed to find out whether a specific microRNA (miR) may contribute to skeletal muscle atrophy in type 2 diabetes. METHODS: Adeno-associated virus (AAV)-mediated skeletal muscle miR-193b overexpression in C57BLKS/J mice, and skeletal muscle miR-193b deficiency in db/db mice were used to explore the function of miR-193b in muscle loss. In C57BL/6 J mice, tibialis anterior-specific deletion of 3-phosphoinositide-dependent protein kinase-1 (PDK1), mediated by in situ AAV injection, was used to confirm whether miR-193b regulates muscle growth through PDK1. Serum miR-193b levels were also analysed in healthy individuals (n = 20) and those with type 2 diabetes (n = 20), and correlations of miR-193b levels with HbA(1c), fasting blood glucose (FBG), body composition, triacylglycerols and C-peptide were assessed. RESULTS: In this study, we found that serum miR-193b levels increased in individuals with type 2 diabetes and negatively correlated with muscle mass in these participants. Functional studies further showed that AAV-mediated overexpression of miR-193b induced muscle loss and dysfunction in healthy mice. In contrast, suppression of miR-193b attenuated muscle loss and dysfunction in db/db mice. Mechanistic analysis revealed that miR-193b could target Pdk1 expression to inactivate the Akt/mammalian target of rapamycin (mTOR)/p70S6 kinase (S6K) pathway, thereby inhibiting protein synthesis. Therefore, knockdown of PDK1 in healthy mice blocked miR-193b-induced inactivation of the Akt/mTOR/S6K pathway and impairment of muscle growth. CONCLUSIONS/INTERPRETATION: Our results identified a previously unrecognised role of miR-193b in muscle function and mass that could be a potential therapeutic target for treating sarcopenia. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-021-05616-y. Springer Berlin Heidelberg 2021-12-16 2022 /pmc/articles/PMC8803817/ /pubmed/34913989 http://dx.doi.org/10.1007/s00125-021-05616-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yang, Shu
Yang, Guangyan
Wu, Han
Kang, Lin
Xiang, Jiaqing
Zheng, Peilin
Qiu, Shanhu
Liang, Zhen
Lu, Yan
Jia, Lijing
MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title_full MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title_fullStr MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title_full_unstemmed MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title_short MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway
title_sort microrna-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the pdk1/akt signalling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803817/
https://www.ncbi.nlm.nih.gov/pubmed/34913989
http://dx.doi.org/10.1007/s00125-021-05616-y
work_keys_str_mv AT yangshu microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT yangguangyan microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT wuhan microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT kanglin microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT xiangjiaqing microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT zhengpeilin microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT qiushanhu microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT liangzhen microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT luyan microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway
AT jialijing microrna193bimpairsmusclegrowthinmousemodelsoftype2diabetesbytargetingthepdk1aktsignallingpathway